🔍

HALEOS LABS LIMITED (HALEOSLABS)

₹1,532.40 -1.71% last close, 16 Oct

📊 NSE: HALEOSLABS 🏢 Pharmaceuticals 📢 Latest filing: 01 Oct 2026 📝 Analysis written: 13 Nov 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, HALEOS LABS's revenue was ₹72.9 Cr (-11.6% year on year, -2.9% on the previous quarter), and net profit ₹1.8 Cr (-58.0% year on year); the operating margin was 12.5%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹72.9	-11.6%	-2.9%
Operating profit	₹9.1	-22.1%	+119.2%
Net profit	₹1.8	-58.0%	+425.8%
EPS (₹)	8.75	-36.4%	+499.3%
Operating margin	12.5%	—	—

Full quarterly financials → Results calendar →

HALEOSLABS delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 75.72% of the HALEOSLABS shares traded on NSE were taken to delivery, against the stock's own 20-session average of 78.86%. That is close to its usual level. Turnover was only ₹11 lakh, so a handful of trades can move this figure.

75.72%Delivery, 16 Oct

78.86%Own 20-session average

0.8×Volume vs its average

₹1,532.40NSE close · -1.71%

Delivery in the last 5 sessions: 76.2% · 86.7% · 91.4% · 68.4% · 75.7%

Delivery across the market →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Haleos Labs 20th AGM: Shareholders Approve All Resolutions Including Dividend and MD Remuneration

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 01 Oct 2026, 08:56 PM

Haleos Labs Limited has submitted the scrutinizer's report and voting results for its 20th Annual General Meeting held on September 30, 2026. All 8 resolutions—including adoption of FY26 financial statements, dividend declaration, re-appointment of directors, and revision of remuneration for Managing Director Mr. TVVSN Murthy—were declared passed with requisite majority. Out of 6,932 total shareholders as of the cut-off date (September 23, 2026), 58 members attended the meeting via video conference. For the MD remuneration and director re-appointment resolutions, 21,79,976 promoter shares were treated as invalid/interested party votes.

All 8 ordinary and special resolutions approved with requisite majority at the 20th AGM
58 members joined the AGM via video conferencing out of 6,932 total shareholders on cut-off date September 23, 2026
Approved resolutions include adoption of FY26 financials, dividend declaration, and revision of remuneration for MD TVVSN Murthy
21,79,976 promoter shares abstained/declared invalid for Resolution 8 (MD Remuneration revision) and Resolution 3

💡 Track the upcoming Q2 FY27 earnings release to assess progress on capacity utilization and product diversification toward its 50+ API target.

Haleos Labs Closes Trading Window from October 1, 2026 for Q2/H1 FY27 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 21 Sep 2026, 03:38 PM

Haleos Labs Limited has announced the closure of its trading window for Designated Persons and specified Connected Persons starting October 1, 2026. The closure is pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the financial results for the quarter and half-year ended September 30, 2026. The window will reopen 48 hours after the declaration of the financial results. The specific date of the Board meeting to consider the results will be communicated separately.

Trading window closes on October 1, 2026
Closure applies to quarter and half-year ended September 30, 2026 results
Window will reopen 48 hours after declaration of financial results
Board meeting date to be intimated separately

💡 Track the upcoming intimation regarding the specific date of the Board meeting for the Q2/H1 FY27 financial results.

Haleos Labs Clears USFDA Inspection with Zero Form 483 Observations at Mahi Drugs Unit

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 18 Sep 2026, 11:57 AM

The USFDA successfully completed an inspection of Mahi Drugs Private Limited, a material subsidiary of Haleos Labs Limited, from September 15 to September 18, 2026. The inspection concluded with zero Form 483 observations, replicating the clean outcome of the previous inspection in January 2025. This facility is located at Jawaharlal Nehru Pharma City, Parawada, Andhra Pradesh, and produces active pharmaceutical ingredients (APIs). A zero-observation outcome reduces compliance uncertainty and supports the company's US-focused supply plans against its TTM revenue base of Rs 332 Cr.

Inspection concluded with zero Form 483 observations
Inspection conducted from September 15, 2026 to September 18, 2026
Replicates the zero-observation outcome from the January 2025 USFDA audit
Site: API facility of material subsidiary Mahi Drugs Private Limited at Parawada, Andhra Pradesh

💡 Track the formal receipt of the Establishment Inspection Report (EIR) from the USFDA and subsequent product launch or export traction from this facility in regulated markets.

Haleos Labs Sets Sept 23 Record Date for FY26 Dividend; 20th AGM on Sept 30, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Sep 2026, 07:01 PM

Haleos Labs Limited has issued an update regarding its 20th Annual General Meeting (AGM), scheduled for September 30, 2026, along with the weblink for the FY2025-26 Annual Report. The company has fixed September 23, 2026, as the record date for determining dividend entitlement for FY26. E-voting for the AGM will commence on September 26, 2026, and conclude on September 29, 2026. The dividend is scheduled to be paid within 30 days of approval by members at the AGM.

20th AGM scheduled for Wednesday, September 30, 2026 at 3:00 PM via video conference
Record date for FY2025-26 dividend set for Wednesday, September 23, 2026
Cut-off date to determine entitlement for e-voting is Wednesday, September 23, 2026
Remote e-voting window runs from Saturday, September 26, 2026 to Monday, September 29, 2026
Dividend payment timeline specified within 30 days from shareholder approval

💡 Investors seeking dividend eligibility must hold shares before the cut-off/record date of September 23, 2026, and can review the detailed Annual Report for operational targets like product expansions.

Haleos Labs Convenes 20th AGM on Sept 30, 2026; Recommends ₹1.50 (15%) Dividend

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 08 Sep 2026, 05:12 PM

Haleos Labs Limited has issued the notice for its 20th Annual General Meeting scheduled for September 30, 2026. Key agenda items include approving a final dividend of ₹1.50 per share (15% on face value of ₹10) for FY26. Shareholders will also vote on the re-appointment and remuneration of Managing Director Mr. TVVSN Murthy, who drew ₹199.36 lakhs in FY26 and holds 56.10% stake with immediate relatives. Additionally, the company seeks appointment of M/s Suryanarayana & Suresh as statutory auditors for a 5-year term.

20th AGM scheduled for September 30, 2026, at 3:00 p.m. via video conferencing
Dividend recommended at ₹1.50 (15%) per equity share of face value ₹10 for FY26
Managing Director Mr. TVVSN Murthy drew total remuneration of ₹199.36 lakhs in FY26
Mr. TVVSN Murthy along with immediate relatives holds 56.10% of the paid-up equity share capital
Appointment of M/s Suryanarayana & Suresh as Statutory Auditors for a 5-year term

💡 Track voting outcomes of the AGM resolutions on September 30, 2026, and look for record date/payout details regarding the ₹1.50 dividend.

Haleos Labs Schedules 20th AGM for September 30, 2026; Cut-Off Date September 23

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 05 Sep 2026, 07:12 PM

Haleos Labs Limited has announced the event calendar for its 20th Annual General Meeting (AGM), scheduled to be held on September 30, 2026, at 3:00 PM via video conferencing. The cut-off date to determine shareholder eligibility for voting and dividend entitlement has been fixed for September 23, 2026. Remote e-voting will commence on September 26, 2026, at 9:00 AM and close on September 29, 2026, at 5:00 PM. CDSL has been appointed as the e-voting platform provider and CSB Associates as the scrutinizer.

20th AGM scheduled for September 30, 2026, at 3:00 PM IST via VC/OAVM
Cut-off date for AGM voting and dividend entitlement set as September 23, 2026
Remote e-voting window runs from September 26, 2026 (9:00 AM) to September 29, 2026 (5:00 PM)
Notice of AGM dispatch scheduled for September 08, 2026

💡 Eligible shareholders seeking voting rights or dividend entitlements should ensure shareholding is in place before the September 23, 2026 cut-off date.

Haleos Labs Sets Sept 23, 2026 Record Date for FY26 Dividend and 20th AGM

🟡 NEUTRAL ⭐ 3/10

DIVIDEND 📅 05 Sep 2026, 07:09 PM

Haleos Labs Limited has fixed September 23, 2026, as the record date to determine shareholder entitlement for the recommended FY2025-26 dividend and voting eligibility. The company's 20th Annual General Meeting (AGM) is scheduled for September 30, 2026. Upon shareholder approval at the AGM, the dividend will be disbursed electronically within 30 days.

Record date fixed as Wednesday, September 23, 2026 for FY26 dividend entitlement
20th Annual General Meeting (AGM) scheduled for September 30, 2026 at 3:00 PM
Dividend payment to be executed within 30 days from approval date at the AGM
Physical dividend warrants discontinued; payouts to be processed strictly via electronic bank credit

💡 Shareholders seeking dividend payout must hold shares prior to the record date (September 23, 2026) and ensure bank account details are linked with their demat accounts.

Haleos Labs Shareholders Reject Executive Remuneration; Approve Director Reappointment & RPTs

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 01 Sep 2026, 11:36 AM

Haleos Labs Limited announced the results of its postal ballot concluded on August 28, 2026. Shareholders approved three out of four resolutions, including the reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director for 5 years (99.99% votes in favour) and material Related Party Transactions for FY27. However, Resolution No. 2 regarding payment of managerial remuneration to Executive Directors was rejected, receiving 82.16% votes against (4,93,502 votes against vs 1,07,148 votes in favour).

Managerial remuneration resolution rejected with 82.16% votes cast against (4,93,502 votes)
Reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director for 5 years approved with 99.99% votes in favour
Material Related Party Transactions for FY 2026-27 approved with 99.99% votes in favour
Material RPTs of the Material Subsidiary for FY 2026-27 approved with 99.99% votes in favour

💡 Track subsequent board actions or revised proposals regarding executive director remuneration caps and alignment with governance norms.

Haleos Labs Issues TDS Circular on ₹1.50 Final Dividend; Record Date Sept 23, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Aug 2026, 03:11 PM

Haleos Labs Limited has issued an informational communication to shareholders regarding Tax Deduction at Source (TDS) on its recommended final dividend for FY 2025-26. The company had proposed a dividend of ₹1.50 per equity share (15% on face value of ₹10), subject to shareholder approval at the 20th AGM. The record date to determine eligibility for the dividend is September 23, 2026. Shareholders seeking lower or nil tax deduction are required to submit requisite tax declarations and documents by September 25, 2026.

Board recommended final dividend of ₹1.50 (15%) per ₹10 equity share for FY 2025-26.
Record date for dividend entitlement fixed as September 23, 2026.
Submission deadline for tax exemption forms (such as Form 121/declarations) is September 25, 2026.
Applicable TDS rate is 10% for resident shareholders with valid PAN, and 20% for invalid or unlinked PAN.

💡 Shareholders eligible for nil or concessional TDS should submit necessary forms (e.g., Form 121) to the RTA by September 25, 2026, and ensure PAN is updated and linked with Aadhaar.

Haleos Labs Appoints ChemWerth President Vincent P. Asaro as Nominee Director for Mahi Drugs

🟢 POSITIVE ⭐ 5/10

MANAGEMENT 📅 05 Aug 2026, 03:19 PM

Haleos Labs Limited has announced key changes at its material subsidiary, Mahi Drugs Private Limited, effective August 5, 2026. Mr. Vincent P. Asaro, the President of ChemWerth Inc. (a global API developer), has been appointed as a Nominee Director, replacing Mr. M. Madhu Rao. This appointment brings over 35 years of international pharmaceutical and financial expertise to the subsidiary's board. Additionally, Annapragada & Co. has been appointed as the Cost Auditor for the subsidiary for the 2026-27 financial year.

Appointment of Mr. Vincent P. Asaro as Nominee Director effective August 5, 2026
Mr. Asaro brings over 35 years of experience in finance, corporate strategy, and pharmaceutical operations
ChemWerth Inc., where Mr. Asaro is President, is a leading global developer and supplier of APIs to regulated markets
Annapragada & Co. appointed as Cost Auditors for the material subsidiary for FY 2026-27
Haleos Labs maintains a market capitalization of Rs 507 Cr with TTM revenue of Rs 348 Cr

💡 Investors should monitor if this board-level alignment with ChemWerth leads to increased order flow or faster approvals in regulated markets like the USA and Brazil, which are key parts of the company's FY2028 growth strategy.

Haleos Labs Approves 5-Year Re-appointment of Two Independent Directors

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 05 Aug 2026, 02:37 PM

Haleos Labs Limited has approved the re-appointment of two Independent Directors, Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam, for a second consecutive five-year term. These appointments will take effect from November 13, 2026, following the conclusion of their current tenures. The decision, made during the board meeting on August 5, 2026, is subject to shareholder approval. This move ensures continuity in the company's independent oversight as it pursues its goal of expanding its product portfolio to 50+ products by FY2028.

Re-appointment of 2 Independent Directors for a second consecutive term of 5 years each.
New terms are scheduled to commence on November 13, 2026, and run through November 12, 2031.
Dr. Mannam Malakondaiah brings nearly 40 years of experience as a former Director General of Police (IPS).
Dr. Srinivas Samavedam has over 26 years of experience in Critical Care Medicine and serves as a consultant at Sindhu Hospitals.
The company maintains a promoter holding of 72.1% as of June 2026.

💡 Investors should monitor the upcoming shareholder voting results to confirm the formalization of these re-appointments.

Haleos Labs Q1 FY27: Net Profit Drops 36% YoY to ₹2.65 Cr on 11.6% Revenue Decline

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 05 Aug 2026, 01:48 PM

Haleos Labs Limited (formerly SMS Lifesciences) reported a weak set of consolidated results for Q1 FY27. Revenue from operations declined 11.6% YoY to ₹72.94 Cr, while net profit attributable to the parent fell 36.3% YoY to ₹2.65 Cr. The decline is notable as cost of materials consumed rose to ₹40.14 Cr from ₹27.73 Cr in the year-ago period, despite the lower topline, indicating significant margin pressure. On a sequential basis, profit improved from a very low base of ₹0.44 Cr in Q4 FY26, but remains well below historical averages.

Consolidated Revenue from Operations fell 11.6% YoY to ₹72.94 Cr from ₹82.50 Cr.
Net Profit attributable to the parent decreased 36.3% YoY to ₹2.65 Cr from ₹4.16 Cr.
Consolidated EPS for the quarter stood at ₹8.75, down from ₹13.75 in Q1 FY26.
Cost of materials consumed increased to ₹40.14 Cr, representing 55% of revenue vs 33.6% in the year-ago quarter.
Board approved the re-appointment of two Independent Directors for a second 5-year term starting November 2026.

💡 Investors should monitor the company's ability to pass on rising raw material costs and track the progress of its product diversification strategy, aiming for 50+ products by FY2028 to reduce reliance on Ranitidine Hcl.

Haleos Labs Seeks Approval for ₹15 Cr Trade Advances and Director Reappointment

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 29 Jul 2026, 07:09 PM

Haleos Labs Limited has initiated a postal ballot to seek shareholder approval for four key resolutions. These include the reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director for a five-year term and the approval of material Related Party Transactions (RPT) for FY 2026-27. A significant component of the RPT approval involves trade advances aggregating up to ₹15 Crores, which represents approximately 4.3% of the company's TTM revenue. The e-voting process concludes on August 28, 2026, with results expected by August 31, 2026.

Reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director for 5 years effective September 2, 2026
Approval sought for trade advances up to ₹15 Crores for related party transactions
E-voting period scheduled from July 30, 2026, to August 28, 2026
Cut-off date for shareholder eligibility set as July 24, 2026
Results of the postal ballot to be declared on or before August 31, 2026

💡 Investors should monitor the voting results on August 31, 2026, to confirm management continuity and oversight of related party transaction limits.

5-Year Director Reappointment and Material RPTs: Haleos Labs Announces Postal Ballot Calendar

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Jul 2026, 03:57 PM

Haleos Labs is seeking shareholder approval via postal ballot for the reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director for a 5-year term. The ballot also includes resolutions for managerial remuneration and the approval of Material Related Party Transactions (RPTs) for FY 2026-27 for both the company and its material subsidiary. E-voting is scheduled to run from July 30, 2026, to August 28, 2026, with results expected by August 31, 2026. These are standard procedural requirements to ensure management continuity and regulatory compliance for operational transactions.

Proposed reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director for a 5-year term
30-day e-voting window scheduled from July 30, 2026, to August 28, 2026
Cut-off date for shareholder eligibility was July 24, 2026
Approval sought for Material Related Party Transactions for the 2026-27 fiscal year
Postal ballot results to be declared by August 31, 2026

💡 Investors should monitor the voting results on August 31, 2026, particularly regarding the Material Related Party Transactions, to ensure they align with minority shareholder interests.

Regulation 74(5) Compliance: Haleos Labs Submits Quarterly RTA Certificate

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jul 2026, 10:53 AM

Haleos Labs Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the period ending June 30, 2026. The filing confirms that the Registrar and Share Transfer Agent (RTA), Aarthi Consultants Private Limited, processed dematerialization requests within the required 15-day timeframe. This process includes the cancellation of physical certificates and updating depository records. This is a standard administrative procedure for listed entities and has no impact on financial performance.

Compliance certificate covers the quarter from April 1, 2026, to June 30, 2026
Dematerialization requests were processed within the statutory 15-day limit
Filing pertains to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018

💡 This is a routine administrative filing; investors should focus on upcoming quarterly earnings for operational updates rather than this procedural document.

View All HALEOSLABS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue from operations grew 11.12% to INR 333.37 Cr in FY25. Segment-wise: Sale of APIs grew 4.67% to INR 204.99 Cr; Intermediates grew 16.33% to INR 98.89 Cr; and Sale of Services grew 197.57% to INR 17.14 Cr. Other sales (Others) declined by 7.77% to INR 12.35 Cr.

Geographic Revenue Split

The company focuses on regulated markets including the US and Brazil, alongside emerging opportunities in frontier economies. Specific percentage splits per region are not disclosed in the available documents.

Profitability Margins

Net Profit Margin improved significantly by 47.19%, rising from 4.36% in FY24 to 6.41% in FY25. Operating Profit Margin increased by 13.29% to 14.45% in FY25 compared to 12.76% in FY24. Return on Net Worth increased by 49.04% to 11.45% due to improved operational profitability.

EBITDA Margin

EBITDA grew 25.89% YoY to INR 48.18 Cr in FY25 from INR 38.27 Cr in FY24. The EBITDA margin stands at 14.45%, reflecting enhanced operational efficiency and a shift toward higher-margin services and intermediates.

Capital Expenditure

The company has undertaken a capital expenditure of INR 145 Cr since its demerger to augment the next leg of growth and enhance manufacturing capabilities.

Credit Rating & Borrowing

The company maintains moderate working capital utilization at approximately 67% for the 12 months ending September 2023. Debt-Equity ratio improved by 25.53%, falling from 0.51 to 0.40 in FY25 due to liability reduction and increased net worth.

⚙️ Operational Drivers

Raw Materials

Specific chemical names are not listed, but raw materials are noted to be subject to price fluctuations and lead-time risks associated with imports. Raw material costs (Cost of Goods Sold) represented 67.39% of revenue in FY25 (INR 224.67 Cr).

Import Sources

The company sources raw materials internationally, with a strategic focus on mitigating risks associated with imports, particularly from China as part of the 'China Plus One' strategy.

Capacity Expansion

Current combined installed capacity is 800 KL. The company is focused on capacity enhancement to meet growing global demand, though specific future KL targets are not quantified.

Raw Material Costs

Cost of goods sold was INR 224.67 Cr in FY25, a 5.63% increase YoY, which is lower than the 11.12% revenue growth, indicating better procurement or pricing power.

Manufacturing Efficiency

Inventory Turnover Ratio improved by 27.46% to 4.93 in FY25. Inventory days decreased by 21.55% from 94.32 days to 74.00 days, reflecting significantly improved manufacturing and sales velocity.

📈 Strategic Growth

Expected Growth Rate

11.12%

Growth Strategy

The company aims to increase its product portfolio to 50+ products by FY2028. Strategy includes backward integration for cost leadership, strategic alliances with global business associates, and focusing on complex, niche APIs in regulated markets like the US and Brazil.

Products & Services

Active Pharmaceutical Ingredients (APIs) such as Ranitidine Hcl, Intermediates, and Contract Manufacturing services.

Brand Portfolio

Haleos Labs (formerly SMS Lifesciences India Limited); Mahi Drugs (Subsidiary).

New Products/Services

Expansion to 50+ products by FY2028 from the current portfolio, focusing on niche and complex API segments.

Market Expansion

Targeting regulated markets (USA, Brazil) and emerging frontier economies to diversify the customer base and reduce geographic risk.

Market Share & Ranking

The company is one of the single-largest manufacturers of Ranitidine Hcl globally, providing a significant competitive advantage in that specific therapeutic segment.

Strategic Alliances

Actively pursuing alliances and partnerships with global business associates to enrich the product portfolio and access new customer segments.

🌍 External Factors

Industry Trends

The industry is shifting toward 'China Plus One' sourcing and niche/complex product segments. Growth is driven by increased health insurance penetration and rising chronic disease prevalence.

Competitive Landscape

Operates in a highly fragmented and regulated bulk drug industry with intense competition from both domestic and international API manufacturers.

Competitive Moat

Moat is built on USFDA-compliant manufacturing facilities (Unit 1 and Mahi Drugs) and global leadership in specific products like Ranitidine Hcl. Sustainability is supported by long-standing customer relationships and economies of scale.

Macro Economic Sensitivity

Highly sensitive to government policies and regulatory reforms which can simplify processes and enhance growth prospects in the pharmaceutical sector.

Consumer Behavior

Increasing demand for generic penetration in regulated markets and growing demand from semi-regulated pharma markets.

Geopolitical Risks

Political and economic instability in export markets and supply chain dependencies on imports are identified as key threats.

⚖️ Regulatory & Governance

Industry Regulations

Subject to Drugs and Cosmetics Act (1940), DPCO (2013), NDPS Act (1985), and USFDA inspections. Unit 1 had one procedural observation in May 2025, while Mahi Drugs had no observations in Jan 2025.

Environmental Compliance

The company enhanced effluent treatment capacities at Unit 1 and Unit 4 to comply with Water, Air, and Environment Protection Acts.

Taxation Policy Impact

Tax expense for FY25 was INR 8.67 Cr, an increase of 43.54% YoY, following the 57.20% increase in Profit Before Tax.

Legal Contingencies

The company created a provision of INR 5.06 Cr for doubtful trade receivables in FY25 to address credit risks. No specific pending court case values were disclosed.

⚠️ Risk Analysis

Key Uncertainties

Regulatory changes in the pharmaceutical sector and USFDA audit outcomes represent the highest impact risks (potential impact not quantified but noted as 'critical').